Recent Analysts’ Ratings Changes for Beam Therapeutics (BEAM)

Several brokerages have updated their recommendations and price targets on shares of Beam Therapeutics (NASDAQ: BEAM) in the last few weeks:

• 10/15/2026 – Beam Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/15/2026 – Beam Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $80.00 price target on the stock.
• 10/14/2026 – Beam Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $65.00 price target on the stock.
• 10/3/2026 – Beam Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 9/23/2026 – Beam Therapeutics was upgraded by William Blair to “strong-buy”.
• 9/13/2026 – Beam Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 9/9/2026 – Beam Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $65.00 price target on the stock.
• 9/5/2026 – Beam Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 8/25/2026 – Beam Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $80.00 price target on the stock.

Insider Buying and Selling

In other news, insider Amy Simon sold 16,667 shares of Beam Therapeutics stock in a transaction on Monday, July 27th. The shares were sold at an average price of $25.74, for a total transaction of $429,008.58. Following the transaction, the insider owned 85,696 shares in the company, valued at $2,205,815.04. This trade represents a 16.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO John Evans sold 25,000 shares of Beam Therapeutics stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $23.57, for a total transaction of $589,250.00. Following the transaction, the chief executive officer owned 1,047,205 shares in the company, valued at $24,682,621.85. This represents a 2.33% decrease in their position. The SEC filing for this sale provides additional information. 3.80% of the stock is currently owned by corporate insiders.

Beam Therapeutics Inc is a biotechnology company developing precision genetic medicines for patients with serious diseases. The company’s platform uses base editing, a form of gene editing designed to make targeted changes to individual DNA letters without creating double-strand breaks. Beam is also advancing related editing technologies and delivery systems intended to improve the precision and effectiveness of genetic treatments.

Beam’s pipeline includes investigational programs for diseases such as sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency and glycogen storage disease type Ia.